This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Discounts in Biotech Keep Pharma M&A Rolling

Tight credit markets are no doubt hindering corporate deals, but the strong likelihood remains for more Big Pharma buyouts.

Biotech firms, particularly struggling micro-caps, are ripe for the picking. And it's no secret that many Big Pharma companies in the next few years will be facing a cliff-like drop in their revenue due to various patent expirations of key drugs.

With this impending revenue decline on the horizon, these large companies are looking to emerging markets and the mid-cap space for growth potential, says Pete Meyers, co-head of health-care investment banking at Deutsche Bank. Some of these pharmaceutical giants will have no choice "but to be acquisitive," he says.

Yes, we have been left waiting to see the next chapter in Roche's July bid for Genentech (DNA) (DNA), a large biotech that is now trading around $75 a share. "The only thing we want to say at the moment is that we are committed to the transaction and aim to reach an agreement with Genentech," a Roche spokesperson said in an email last week.

According to a recent Reuters report, Roche had been seeking a $45 billion loan. Investors are clearly skeptical that the Big Pharma will be able to borrow enough money for the deal -- which Genentech rejected at the proposed price of $89-a-share.

But smaller deals are getting done. Just a week after inking a deal to buy Omrix Biopharmaceuticals (OMRI) for $338 million, Johnson & Johnson (JNJ - Get Report) on Monday said it would buy breast implant company Mentor (MNT) for $1.1 billion.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
JNJ $100.34 0.00%
LLY $73.58 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs